Research and Development

Debiopharm is teaming up with researchers at Yale University to develop Debio 1036, a first-in-class inhibitor for autoimmune and inflammatory …

Roche’s cancer drug Avastin is as effective at treating wet AMD as Novartis’ Lucentis, which is licensed for the eye …

SERVICE INSIGHT Currently, the pharma industry is experiencing an unprecedented wave of blockbuster drug patent expiries. There is a lack …

This week’s CRO news roundup includes Omnicare CR and LAB Research changing hands, Q1 financials for ICON and PPD and …

Astellas Pharma has made four new senior appointments to its US-based global development team. Former Eli Lilly vice president of …

Generics giant Teva has acquired Cephalon for $6.8 billion and says the deal will make it a leading specialty pharmaceutical …

Boehringer Ingelheim has begun enrolling patients in North America for a phase III trial of its chronic hepatitis C virus …

Four deaths have been reported in a late-stage study of Pfizer’s arthritis drug tofacitinib. Three of the deaths are thought …

Swedish pharma company BioInvent International has appointed Sten Westerberg to the newly-created position of vice president investor relations. Sten is …

Amgen and UCB have announced strong results from a phase II study of their new postmenopausal osteoporosis treatment. Most existing …

Trevor Smith has been appointed chief executive of Takeda Pharmaceuticals Europe. Smith brings more than 30 years of pharmaceutical experience …

 Over $78 billion is spent every year in the clinical trial market in the pursuit of bringing new drugs and …

US biopharmaceutical company Novavax has reorganised its senior management. The changes see former executive chairman Stanley Erck take on the …

Warner Chilcott is looking to cut 500 jobs from its European operations as it seeks to minimise the impact of …

Our contract research news round-up features updates from BioClinica, Vyteris, CROMSOURCE, Quintiles, Imperial/D. Anderson and PRA International. Clinical trial management …